Related Experiment Videos
Therapy for ocular toxoplasmosis
A Rothova1, C Meenken, H J Buitenhuis
1Department of Ophthalmology, Academic Medical Centre, Amsterdam, The Netherlands.
American Journal of Ophthalmology
|April 15, 1993
Summary
Current ocular toxoplasmosis treatments show no significant difference in inflammatory activity duration. Retinal lesion size, not treatment, is the key predictor, though pyrimethamine may reduce lesion size but increases side effects.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Parasitology
Background:
- Ocular toxoplasmosis, a parasitic infection, can cause significant visual impairment.
- Current therapeutic strategies involve various triple-drug combinations, but their comparative efficacy remains under investigation.
Purpose of the Study:
- To evaluate the efficacy of three different triple-drug regimens for ocular toxoplasmosis.
- To identify factors influencing the duration of inflammatory activity and recurrence rates.
Main Methods:
- A prospective multicenter study involving 149 patients with ocular toxoplasmosis.
- Comparison of three treatment groups: pyrimethamine, sulfadiazine, and corticosteroids; clindamycin, sulfadiazine, and corticosteroids; and trimethoprim, sulfamethoxazole, and corticosteroids.
- Exclusion of patients with peripheral retinal lesions from systemic treatment.
Main Results:
- No significant difference in the duration of inflammatory activity was observed between treated and untreated patients (P = .5).
- Retinal lesion size was the most significant predictor of inflammatory activity duration (P < .001).
- Pyrimethamine treatment showed a higher reduction in lesion size (49%) compared to untreated patients (20%) (P < .01), but also had the most frequent side effects (26%).
- The overall recurrence rate after three years was 49%, with no difference between treated and untreated groups (P = .6).
Conclusions:
- Current therapeutic strategies for ocular toxoplasmosis do not significantly alter the duration of inflammatory activity.
- Retinal lesion size is a critical factor in disease duration, independent of treatment.
- While pyrimethamine may reduce lesion size, its associated side effects warrant consideration. Recurrence rates are high and unaffected by current treatments.